Product
DCR-STAT3
1 clinical trial
3 indications
Indication
Solid TumorIndication
AdultIndication
Refractory TumorClinical trial
An Open-label, Phase 1, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-STAT3 in Adults With Refractory Solid TumorsStatus: Recruiting, Estimated PCD: 2025-07-01